Autopsy report · NCT03382574

Pilot Study of Denosumab in BRCA1/2 Mutation Carriers Scheduled for Risk-Reducing Salpingo-Oophorectomy

“it was decided that due to lack of accrual on the trial, and low potential for accruing over the near future, the trial will be shut down.”

The sponsor’s own words in the registry.

Life of this trial

• Registered 1 year 3 months before it started.
• Ran for about 2 years 7 months before it stopped.
• 2 participants enrolled.
• Results were posted on the registry 8 months after it ended.

Vital statistics

Status

Terminated

Phase

Early Phase 1

Sponsor

National Cancer Institute (NCI)

Sponsor type

US National Institutes of Health

Conditions

Ovarian Carcinoma

Interventions

Denosumab; Salpingo-Oophorectomy

Participants

2

Sites

6

Countries

Israel, United States

Trials that died the same way

• Loncastuximab Tesirine for the Treatment of Relapsed or Refractory B-Cell Malignancies
  “The trial closed early due to slow accrual.” (76% match in meaning)
• A Study to Learn About the Study Medicine (Nirmatrelvir Plus Ritonavir) in Pregnant Women With COVID-19
  “The trial prematurely terminated due to the inability to recruit the planned number of subjects. The decision to terminate the trial was not based on any safety concerns.” (73% match in meaning)
• A Study to Learn About the Effect of Avelumab First-Line Maintenance in Canadian People With Advanced Bladder Cancer
  “The trial was terminated for strategic reasons. The decision was not based on any safety and/or efficacy concerns.” (71% match in meaning)
• Study of ARC-520 With or Without Other Drugs Used in the Treatment of Chronic Chronic Hepatitis B Virus (HBV)
  “Company decision to discontinue trial” (71% match in meaning)
• Regorafenib-pembrolizumab vs. TACE/TARE in Intermediate Stage HCC Beyond Up-to-7
  “The trial ended earlier than planned due to slow enrolment, which has made it unfeasible to achieve the target sample size within a reasonable timeframe. Consequently, a business decision has been made to discontinue funding for the trial.” (71% match in meaning)

Look deeper

• The official registry record (the source of truth)
• Record history: every change the sponsor made
• Open it in the database

Everything here comes from the current ClinicalTrials.gov record. The timeline uses the record’s dates; dates marked planned are the sponsor’s plans. The cause of death is an automatic, unverified label. This is research information, not medical advice.